raltegravir

Type: Keyphrase
Name: raltegravir
First reported Oct 28 2014 - Updated Oct 28 2014 - 1 reports

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers

Faldaprevir is a potent HCV NS3/4A protease inhibitor and an inhibitor of UDP-glucuronosyltransferase-1A1, which is involved in raltegravir clearance. Raltegravir, an HIV integrase inhibitor, may be used in combination with HCV treatment in HCV/HIV co-infected ... [Published Journal of Clinical Pharmacology - Oct 28 2014]
First reported Oct 25 2014 - Updated Oct 25 2014 - 1 reports

PIs and Raltegravir Favored Over NNRTIs for Frail and Older People

5th International Workshop onHIV and Aging.October 21-22, 2014 Baltimore. 5th International Workshop on HIV and Aging. October 21-22, 2014. BaltimoreMark MascoliniProtease inhibitors (PIs) and the integrase inhibitor raltegravir got prescribed significantly ... [Published National AIDS Treatment Advocacy Project - Oct 25 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Tolerability, adherence and completion of new occupational post-exposure prophylaxis regimen (tenofovir + emtricitabine and raltegravir)

ID WeekOct 8-12 2014Philadelphia Reported by Jules LevinIDSA Oct 8-12 2014 Philadelphia, PABock I1,2, Felsen U1,2, Catalano M1,2, Hacker S1, Zingman BS1,2Montefiore Medical Center, Bronx, NY1; Albert Einstein College of Medicine, Bronx, NY2Program ab ... [Published National AIDS Treatment Advocacy Project - Oct 23 2014]
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

NNRTIs and protease inhibitors both good for first ART, channelling affects choices

In thesecond study, Michael Saag from the University of Alabama at Birmingham and colleagueslooked at factors that affect how providers select initial antiretroviral drugclasses for specific patients, for example, whether doctors prescribe certaindrugs ... [Published Aidsmap - Oct 22 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

U.K. Updates PEP Guidelines: Raltegravir Replaces PIs and No Indication if Positive Partner Has an Undetectable Viral Load

The switch to raltegravir as the third active drug in PEP should improve tolerability. Fewer side effects may increase the number of people who come forward to use PEP. It could also increase the number of people who complete the monthly course of PEP ... [Published The Body PRO - Oct 21 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

[Correspondence] Raltegravir and rifampicin in patients with HIV and tuberculosis

Beatriz Grinsztejn and colleagues 1 presented data suggesting that a raltegravir dose of 400 mg twice daily is equally effective and better tolerated than the currently recommended dose of 800 mg twice daily in patients with HIV who are receiving rifampicin ... [Published Lancet Infectious Diseases - Oct 21 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

High Rate of NPEP Completion, Good Safety, With Raltegravir Plus TDF/FTC

ID WeekOct 8-12 2014Philadelphia IDWeek 2014, October 8-12, 2014, PhiladelphiaMark MascoliniMore than 4 in 5 people in a Houston study completed nonoccupational postexposure prophylaxis (NPEP) with raltegravir plus tenofovir/emtricitabine (TDF/FTC) [1]. ... [Published National AIDS Treatment Advocacy Project - Oct 17 2014]
First reported Oct 15 2014 - Updated Oct 16 2014 - 2 reports

A 28-Day High-Dose Safety and Pharmacokinetics Study of Raltegravir in Healthy Subjects

ID WeekOct 8-12 2014Philadelphia Reported by Jules LevinIDSA 2014, October 8-12, 2014, PhiladelphiaKrishna R1, Rizk ML1, Schulz V1, Bruggencate-Broeders ten J1, Liu R1, Larson P1, and Farha KA21Merck Research Laboratories, Merck & Co., Inc., Whitehouse ... [Published National AIDS Treatment Advocacy Project - Oct 16 2014]
First reported Oct 11 2014 - Updated Oct 11 2014 - 1 reports

Gender, Depression, Heart and Liver Disease Affect First-Line ART Choice in US

ID WeekOct 8-12 2014Philadelphia IDWeek 2014, October 8-12, 2014, PhiladelphiaMark MascoliniWomen and people with depression or liver disease were less likely to start antiretroviral therapy (ART) with a nonnucleoside (NNRTI) in a 1215-person 8-clinic ... [Published National AIDS Treatment Advocacy Project - Oct 11 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

HIV: Non-Efavirenz Regimens Effective in Initial Treatment

Several regimens that exclude efavirenz have similar efficacy in the initial treatment of HIV, according to results from a phase 3 AIDS Clinical Trials Group randomized controlled trial published online October 6 in the Annals of Internal Medicine . The ... [Published General Medicine eJournal - Oct 10 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

HIV Attachment Inhibitor BMS-663068 Compares Well to Boosted Atazanavir at 24 Weeks

In its bid to become the first approved member of a new class of HIV medications, the attachment inhibitor BMS-663068, also known as "068" or fostemsavir, showed similar efficacy to ritonavir (Norvir)-boosted atazanavir (Reyataz) in Phase 2b study results ... [Published The Body - Oct 10 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in ...

Ongoing HIV-1 replication in lymphoid cells is one explanation of the persistence of HIV-1 reservoirs despite highly active antiretroviral therapy (cART). We tested the potential of cART intensification by Maraviroc plus Raltegravir to decrease proviral ... [Published 7thSpace - Oct 07 2014]

Quotes

...The researchers proposed that their findings demonstrate "a clinical attitude towards antiretroviral selection that may incorporate global judgment about overall health status and vulnerability beyond traditional virological and immunological markers of HIV disease."
"What these guidelines have in common is that they get a group of experts together, they review all available data, and then they make recommendations for clinicians" said Roy Gulick, MD, from Weill Cornell Medical College in New York City, and cochair of the US Department of HealthDepartment of Health and Human Services...
concluded. "As more choices for HIV therapy become available, factors that"
Given the elevated risk of osteoporosis in people living with HIV -- especially in men over 50 and postmenopausal women -- "clinicians need to be aware of optimal screening and management of bone disease" according to Todd T Brown, M D , Ph D , of Johns Hopkins University, who gave a review of the subject at IDWeek 2014 in Philadelphia

More Content

All (49) | News (39) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Effect of faldaprevir on raltegravir pharmacoki... [Published Journal of Clinical Pharmacology - Oct 28 2014]
Merck & Co third-qtr disappoints, as earnings p... [Published Pharma Letter - Oct 27 2014]
PIs and Raltegravir Favored Over NNRTIs for Fra... [Published National AIDS Treatment Advocacy Project - Oct 25 2014]
Tolerability, adherence and completion of new o... [Published National AIDS Treatment Advocacy Project - Oct 23 2014]
Same Data, Contradictory HIV Guidelines [Published General Medicine eJournal - Oct 22 2014]
NNRTIs and protease inhibitors both good for fi... [Published Aidsmap - Oct 22 2014]
Preventing and Treating HIV-Associated Bone Dis... [Published The Body - Oct 22 2014]
U.K. Updates PEP Guidelines: Raltegravir Replac... [Published The Body PRO - Oct 21 2014]
ICAAC 2014: Challenges to Stem Cell Transplanta... [Published The Body PRO - Oct 21 2014]
[Correspondence] Raltegravir and rifampicin in ... [Published Lancet Infectious Diseases - Oct 21 2014]
High Rate of NPEP Completion, Good Safety, With... [Published National AIDS Treatment Advocacy Project - Oct 17 2014]
A 28-Day High-Dose Safety and Pharmacokinetics ... [Published National AIDS Treatment Advocacy Project - Oct 16 2014]
Approval of Sofosbuvir/Ledipasvir Was Expected,... [Published The Body - Oct 15 2014]
Safety, Tolerability, and Antiretroviral Activi... [Published National AIDS Treatment Advocacy Project - Oct 15 2014]
Hypoxia Induces Dysregulation of Lipid Metaboli... [Published Sexual Development - Oct 14 2014]
Gender, Depression, Heart and Liver Disease Aff... [Published National AIDS Treatment Advocacy Project - Oct 11 2014]
HIV: Non-Efavirenz Regimens Effective in Initia... [Published General Medicine eJournal - Oct 10 2014]
HIV Attachment Inhibitor BMS-663068 Compares We... [Published The Body - Oct 10 2014]
Efavirenz-free regimens prove effective for ini... [Published Medical News Today - Oct 08 2014]
Failure of combined antiretroviral therapy inte... [Published 7thSpace - Oct 07 2014]
Nonnucleoside Reverse Transcriptase Inhibitor–S... [Published Annals of Internal Medicine - Oct 07 2014]
News from Annals of Internal Medicine tip sheet... [Published EurekAlert! - Oct 06 2014]
Effective treatments available for HIV patients... [Published Medical Xpress - Oct 06 2014]
Einstein & Montefiore Investigators Present Res... [Published Newswise - Oct 01 2014]
FDA approves two new doses of elvitegravir, in ... [Published Project Inform - Sep 30 2014]
New FDA HIV Drug Approvals Unlikely to Have Muc... [Published The Body - Sep 29 2014]
Elvitegravir / Vitekta FDA Approval [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
Persistence of Virus Reservoirs in ART-Treated ... [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
For HIV/HCV Coinfected Patients, 3D With Ribavi... [Published The Body - Sep 26 2014]
Gilead receives approval for two HIV-1 cocktail... [Published Drugtopics.com - Sep 26 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - Sep 15 2014]
Can we reduce human endogenous retroviruses or HERVs with a treatment? #MSBlog #MSResearch "Just arrived back from Boston; exhausted physically, mentally and no doubt more to come with jet-lag. One of the highlights for me at ECTRIMS was the interest ...
[Department of Error] Department of Error [Published The Lancet - Sep 05 2014]
Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735–43—The ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
[Articles] Ritonavir-boosted darunavir combined... [Published The Lancet online - Aug 05 2014]
Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. ...
Charcot Project: INSPIRE Trial fully recruited [Published Multiple Sclerosis Research - Jul 30 2014]
The INSPIRE Study is now fully recruited. #MSBlog #MSResearch "In response to several requests, I can now confirm that recruitment for the INSPIRE Study is now complete. The study will be closed when the last subject completes 6 months, i.e. early ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.